Although CEP-18770 (delanzomib) showed promising results in promoting apoptosis in human multiple myeloma cell lines and patient-derived cells by suppressing NF-κB–mediated mediated signaling pathways and by inhibiting endothelial cell survival, and RANKL-induced osteoclastogenesis in vitro (Piva et al., 2008), development of delanzomib for myeloma was discontinued owing to its dose-limiting toxicities (Vogl et al., 2017). This evidence concerns the gene NFKB1 and plasma cell myeloma.